Paper32023707
[Hepatocellular carcinoma-derived exosomal miRNA expression and its clinical value].
Wu MN and 3 others. Zhonghua Gan Zang Bing Za Zhi, 2020. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. [Hepatocellular carcinoma-derived exosomal miRNA expression and its clinical value]. Papers, record 32023707. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32023707
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Exosomes | Major topic |
| Liver Neoplasms | Major topic |
| MicroRNAs | Major topic |
| Humans | |
| RNA, Long Noncoding | |
| Tumor Microenvironment |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81673241, 31872738 | National Natural Science Foundation of China | PubMed | ||
| BE2016698 | The Key Study Project of Jiangsu Province of China | PubMed |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27890434 | miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway. | Biomed Pharmacother | 2017 | https://conductscience.org/library/papers/27890434 | PubMed |
| 2 | 28781655 | HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle microRNAs. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28781655 | PubMed |
| 3 | 25686836 | Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. | Oncotarget | 2015 | https://conductscience.org/library/papers/25686836 | PubMed |
| 4 | 28288874 | Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. | Cancer Lett | 2017 | https://conductscience.org/library/papers/28288874 | PubMed |
| 5 | 28781949 | miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. | FEBS Open Bio | 2017 | https://conductscience.org/library/papers/28781949 | PubMed |
| 6 | 29510736 | MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29510736 | PubMed |
| 7 | 26514126 | Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. | J Hematol Oncol | 2015 | https://conductscience.org/library/papers/26514126 | PubMed |
| 8 | 25308172 | miR-122--a key factor and therapeutic target in liver disease. | J Hepatol | 2015 | https://conductscience.org/library/papers/25308172 | PubMed |
| 9 | 25503676 | Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells. | Hepatology | 2015 | https://conductscience.org/library/papers/25503676 | PubMed |
| 10 | 28098858 | miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. | Int J Oncol | 2017 | https://conductscience.org/library/papers/28098858 | PubMed |
| 11 | 27278244 | Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). | Oncol Rep | 2016 | https://conductscience.org/library/papers/27278244 | PubMed |
| 12 | 27463001 | Exosomes: small vesicles with big roles in hepatocellular carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/27463001 | PubMed |
| 13 | 28189396 | Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B. | Clin Res Hepatol Gastroenterol | 2017 | https://conductscience.org/library/papers/28189396 | PubMed |
| 14 | 29313949 | Cancer statistics, 2018. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/29313949 | PubMed |
| 15 | 28814883 | Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. | Onco Targets Ther | 2017 | https://conductscience.org/library/papers/28814883 | PubMed |
| 16 | 29637568 | Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. | Hepatology | 2018 | https://conductscience.org/library/papers/29637568 | PubMed |
| 17 | 27878280 | Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma. | Oncol Rep | 2017 | https://conductscience.org/library/papers/27878280 | PubMed |
| 18 | 28750499 | Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma. | Minerva Med | 2018 | https://conductscience.org/library/papers/28750499 | PubMed |
| 19 | 30148162 | Exosomes in the Oncobiology, Diagnosis, and Therapy of Hepatic Carcinoma: A New Player of an Old Game. | Biomed Res Int | 2018 | https://conductscience.org/library/papers/30148162 | PubMed |
| 20 | 29858059 | Hepatocellular Carcinoma Cell-Secreted Exosomal MicroRNA-210 Promotes Angiogenesis In Vitro and In Vivo. | Mol Ther Nucleic Acids | 2018 | https://conductscience.org/library/papers/29858059 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40620503 | Non-coding RNAs in alcohol-associated liver disease. | Liver Res | 2025 | https://conductscience.org/library/papers/40620503 | PubMed |
| 38238951 | [miR-200a involvement in the biological behavior of hepatoma carcinoma cells by targeting the regulatory expression of mesenchymal-epithelial transition factor]. | Zhonghua Gan Zang Bing Za Zhi | 2023 | https://conductscience.org/library/papers/38238951 | PubMed |
| 36891706 | [Research progress and clinical application value of exosomal circRNAs in hepatocellular carcinoma]. | Zhonghua Gan Zang Bing Za Zhi | 2022 | https://conductscience.org/library/papers/36891706 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32023707
GET https://conductscience.org/api/papers/v1/32023707/references?page=2